These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 35912897)

  • 1. Ferric citrate for the treatment of hyperphosphatemia and anemia in patients with chronic kidney disease: a meta-analysis of randomized clinical trials.
    Li L; Zheng X; Deng J; Zhou J; Ou J; Hong T
    Ren Fail; 2022 Dec; 44(1):1112-1122. PubMed ID: 35912897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Ferric Citrate on Hyperphosphatemia among Chinese Patients with Chronic Kidney Disease Undergoing Hemodialysis: A Phase III Multicenter Randomized Open-Label Active-Drug-Controlled Study.
    Wang Y; Chen X; Zhu H; Guo Z; Yang Y; Luo P; He Y; Xu Y; Ji D; Gao X; Sun X; Xing C; Wang Y; Wang X; Zhao S; Guan Y; Lin H; Zhong A; Shui H; Shao F; Lv L; Yan Y; Sun X; Zhang L
    Am J Nephrol; 2023; 54(11-12):479-488. PubMed ID: 37812931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.
    Patel L; Bernard LM; Elder GJ
    Clin J Am Soc Nephrol; 2016 Feb; 11(2):232-44. PubMed ID: 26668024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
    Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE;
    Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD.
    Yokoyama K; Hirakata H; Akiba T; Fukagawa M; Nakayama M; Sawada K; Kumagai Y; Block GA
    Clin J Am Soc Nephrol; 2014 Mar; 9(3):543-52. PubMed ID: 24408120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using iron-based phosphate binders in phosphate reduction and anemia improvement in patients receiving dialysis: a meta-analysis of randomized controlled trials.
    Zhu Y; Rao J; Liao X; Ou J; Li W; Xue C
    Int Urol Nephrol; 2021 Sep; 53(9):1899-1909. PubMed ID: 33675476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ferric citrate in the management of hyperphosphataemia and iron deficiency anaemia: A meta-analysis in patients with chronic kidney disease.
    Choi YJ; Noh Y; Shin S
    Br J Clin Pharmacol; 2021 Feb; 87(2):414-426. PubMed ID: 32470149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of Ferric Citrate in Hyperphosphatemia and Iron Deficiency Anemia in Non Dialysis CKD Patients.
    Nand N; Giri K; Jain D
    J Assoc Physicians India; 2019 Apr; 67(4):53-56. PubMed ID: 31311220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress in pharmacotherapy for the treatment of hyperphosphatemia in renal failure.
    Cernaro V; Longhitano E; Calabrese V; Casuscelli C; Di Carlo S; Spinella C; Gembillo G; Santoro D
    Expert Opin Pharmacother; 2023; 24(15):1737-1746. PubMed ID: 37527180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and effectiveness of lanthanum carbonate for hyperphosphatemia in chronic kidney disease (CKD) patients: a meta-analysis.
    Zhao L; Liu A; Xu G
    Ren Fail; 2021 Dec; 43(1):1378-1393. PubMed ID: 34602015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
    Navaneethan SD; Palmer SC; Craig JC; Elder GJ; Strippoli GF
    Am J Kidney Dis; 2009 Oct; 54(4):619-37. PubMed ID: 19692157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs?
    St. Peter WL; Wazny LD; Weinhandl E; Cardone KE; Hudson JQ
    Drugs; 2017 Jul; 77(11):1155-1186. PubMed ID: 28584909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5.
    Block GA; Fishbane S; Rodriguez M; Smits G; Shemesh S; Pergola PE; Wolf M; Chertow GM
    Am J Kidney Dis; 2015 May; 65(5):728-36. PubMed ID: 25468387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ferric citrate spans mineral metabolism and anemia domains in ESRD: a review of efficacy and safety data.
    Sinsakul M; Rodby R; Umanath K; Niecestro R; Dwyer JP
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):705-10. PubMed ID: 25242077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel iron-containing phosphate binders for treatment of hyperphosphatemia.
    Schmid H; Lederer SR
    Expert Opin Pharmacother; 2015; 16(14):2179-91. PubMed ID: 26293683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel iron-containing phosphate binders and anemia treatment in CKD: oral iron intake revisited.
    Nakanishi T; Hasuike Y; Nanami M; Yahiro M; Kuragano T
    Nephrol Dial Transplant; 2016 Oct; 31(10):1588-94. PubMed ID: 26142396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Efficacy and Acceptability of 12 Phosphorus-Lowering Drugs in Adults with Hyperphosphatemia and Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis.
    Luo H; Feng J; Xue G; Zhang Y; Li Y; Huang X; Chen X; You S; Dong H; Li L; Li J; Xiao H; Ai X; Li X; Huang B
    Blood Purif; 2023; 52(7-8):609-620. PubMed ID: 37591223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects and safety of iron-based phosphate binders in dialysis patients: a systematic review and meta-analysis.
    Zhai CJ; Yu XS; Yang XW; Sun J; Wang R
    Ren Fail; 2015 Feb; 37(1):7-15. PubMed ID: 25350834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meta-analysis of the efficacy and safety of sevelamer as hyperphosphatemia therapy for hemodialysis patients.
    Zeng Q; Zhong Y; Yu X
    Ren Fail; 2023 Dec; 45(1):2210230. PubMed ID: 37272189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial.
    Dwyer JP; Sika M; Schulman G; Chang IJ; Anger M; Smith M; Kaplan M; Zeig S; Koury MJ; Blumenthal SS; Lewis JB;
    Am J Kidney Dis; 2013 May; 61(5):759-66. PubMed ID: 23369827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.